Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Unchanged Levels of Soluble CD14 and IL-6 Over Time Predict Serious Non-AIDS Events in HIV-1-Infected People.

Sunil M, Nigalye M, Somasunderam A, Martinez ML, Yu X, Arduino RC, Utay NS, Bell TK.

AIDS Res Hum Retroviruses. 2016 Jul 26. [Epub ahead of print]

PMID:
27344921
2.

The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.

Jacobson JM, Zheng L, Wilson CC, Tebas P, Matining RM, Egan MA, Eldridge J, Landay AL, Clifford DB, Luetkemeyer AF, Tiu J, Martinez AL, Janik J, Spitz TA, Hural J, McElrath J, Frahm N; ACTG A5281 Protocol Team..

J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):163-71. doi: 10.1097/QAI.0000000000000830.

PMID:
26761518
3.

The role of BMI change on smoking abstinence in a sample of HIV-infected smokers.

Buchberg MK, Gritz ER, Kypriotakis G, Arduino RC, Vidrine DJ.

AIDS Care. 2016;28(5):603-7. doi: 10.1080/09540121.2015.1120854.

PMID:
26666313
4.

Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.

Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, Eron JJ, Berzins B, Robertson K, Landay A, Ofotokun I, Brown T; AIDS Clinical Trials Group A5303 Study Team..

Clin Infect Dis. 2015 Oct 1;61(7):1179-88. doi: 10.1093/cid/civ455.

5.

Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS; AIDS Clinical Trials Group (ACTG) A5257 Team..

Clin Infect Dis. 2015 Jun 15;60(12):1842-51. doi: 10.1093/cid/civ193.

6.

Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial.

French MA, Cozzi-Lepri A, Arduino RC, Johnson M, Achhra AC, Landay A; INSIGHT SMART Study Group..

AIDS. 2015 Apr 24;29(7):847-51. doi: 10.1097/QAD.0000000000000618.

7.

Mediators of a smoking cessation intervention for persons living with HIV/AIDS.

Vidrine DJ, Kypriotakis G, Li L, Arduino RC, Fletcher FE, Tamí-Maury I, Gritz ER.

Drug Alcohol Depend. 2015 Feb 1;147:76-80. doi: 10.1016/j.drugalcdep.2014.12.003.

8.

Perceptions of barriers and facilitators to cervical cancer screening among low-income, HIV-infected women from an integrated HIV clinic.

Fletcher FE, Buchberg M, Schover LR, Basen-Engquist K, Kempf MC, Arduino RC, Vidrine DJ.

AIDS Care. 2014;26(10):1229-35. doi: 10.1080/09540121.2014.894617.

9.

The influence of HIV disease events/stages on smoking attitudes and behaviors: project STATE (Study of Tobacco Attitudes and Teachable Events).

Vidrine DJ, Fletcher FE, Buchberg MK, Li Y, Arduino RC, Gritz ER.

BMC Public Health. 2014 Feb 11;14:149. doi: 10.1186/1471-2458-14-149.

10.

Long-term outcomes of a cell phone-delivered intervention for smokers living with HIV/AIDS.

Gritz ER, Danysh HE, Fletcher FE, Tami-Maury I, Fingeret MC, King RM, Arduino RC, Vidrine DJ.

Clin Infect Dis. 2013 Aug;57(4):608-15. doi: 10.1093/cid/cit349.

11.

Cervical cancer screening adherence among HIV-positive female smokers from a comprehensive HIV clinic.

Fletcher FE, Vidrine DJ, Tami-Maury I, Danysh HE, King RM, Buchberg M, Arduino RC, Gritz ER.

AIDS Behav. 2014 Mar;18(3):544-54. doi: 10.1007/s10461-013-0480-6.

12.

Long-term effects of intermittent IL-2 in HIV infection: extended follow-up of the INSIGHT STALWART Study.

Markowitz N, Lopardo G, Wentworth D, Gey D, Babiker A, Fox L, Tavel J; STALWART Study Group..

PLoS One. 2012;7(10):e47506. doi: 10.1371/journal.pone.0047506.

13.

Toscana meningoencephalitis: a comparison to other viral central nervous system infections.

Jaijakul S, Arias CA, Hossain M, Arduino RC, Wootton SH, Hasbun R.

J Clin Virol. 2012 Nov;55(3):204-8. doi: 10.1016/j.jcv.2012.07.007.

14.

Factors associated with nonadherence to antiretroviral therapy in HIV-positive smokers.

King RM, Vidrine DJ, Danysh HE, Fletcher FE, McCurdy S, Arduino RC, Gritz ER.

AIDS Patient Care STDS. 2012 Aug;26(8):479-85. doi: 10.1089/apc.2012.0070.

15.

Absence of XMRV in peripheral blood mononuclear cells of ARV-treatment naïve HIV-1 infected and HIV-1/HCV coinfected individuals and blood donors.

Gingaras C, Danielson BP, Vigil KJ, Vey E, Arduino RC, Kimata JT.

PLoS One. 2012;7(2):e31398. doi: 10.1371/journal.pone.0031398.

16.

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Eron JJ Jr; ACTG A5262 Team..

AIDS. 2011 Nov 13;25(17):2113-22. doi: 10.1097/QAD.0b013e32834bbaa9.

17.

Efficacy of cell phone-delivered smoking cessation counseling for persons living with HIV/AIDS: 3-month outcomes.

Vidrine DJ, Marks RM, Arduino RC, Gritz ER.

Nicotine Tob Res. 2012 Jan;14(1):106-10. doi: 10.1093/ntr/ntr121.

18.

Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).

Pett SL, Carey C, Lin E, Wentworth D, Lazovski J, Miró JM, Gordin F, Angus B, Rodriguez-Barradas M, Rubio R, Tambussi G, Cooper DA, Emery S; INSIGHT-ESPRIT Study Group..

HIV Med. 2011 Apr;12(4):219-27. doi: 10.1111/j.1468-1293.2010.00875.x.

19.

Dendritic cell-mediated HIV-1 infection of T cells demonstrates a direct relationship to plasma viral RNA levels.

Arora R, Bull L, Siwak EB, Thippeshappa R, Arduino RC, Kimata JT.

J Acquir Immune Defic Syndr. 2010 Jun;54(2):115-21. doi: 10.1097/QAI.0b013e3181daaf98.

20.

Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.

Tavel JA; INSIGHT STALWART Study Group., Babiker A, Fox L, Gey D, Lopardo G, Markowitz N, Paton N, Wentworth D, Wyman N.

PLoS One. 2010 Feb 23;5(2):e9334. doi: 10.1371/journal.pone.0009334.

Items per page

Supplemental Content

Loading ...
Support Center